Literature DB >> 19289744

Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.

F Leypoldt1, A Münchau, F Moeller, M Bester, C Gerloff, C Heesen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19289744     DOI： 10.1212/01.wnl.0000344567.51394.e3

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  13 in total

Review 1.  [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].

Authors:  O Aktas; J Ingwersen; B Kieseier; P Küry; R Hohlfeld; H-P Hartung
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

2.  Multiple sclerosis: closing in on an oral treatment.

Authors:  Roland Martin
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

Review 3.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 4.  Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-08       Impact factor: 5.749

Review 5.  Fingolimod is a potential novel therapy for multiple sclerosis.

Authors:  Orhan Aktas; Patrick Küry; Bernd Kieseier; Hans-Peter Hartung
Journal:  Nat Rev Neurol       Date:  2010-06-15       Impact factor: 42.937

Review 6.  Treatment of multiple sclerosis: current concepts and future perspectives.

Authors:  Dorothea Buck; Bernhard Hemmer
Journal:  J Neurol       Date:  2011-06-03       Impact factor: 6.682

7.  Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

Authors:  Enrico C Lallana; Camilo E Fadul
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

Review 8.  Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.

Authors:  Claudio Gasperini; Serena Ruggieri
Journal:  Drug Des Devel Ther       Date:  2012-07-19       Impact factor: 4.162

9.  Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patients.

Authors:  James J Marriott
Journal:  J Cent Nerv Syst Dis       Date:  2011-03-16

10.  Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod.

Authors:  Claudio Gasperini; Serena Ruggieri; Chiara Rosa Mancinelli; Carlo Pozzilli
Journal:  Ther Clin Risk Manag       Date:  2013-03-03       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.